OIG Advisory Opinion 25-11: Key Compliance Insights for Manufacturers

Start
In Advisory Opinion 25-11 issued December 15, 2025, the Department of Health and Human Services Office of Inspector General (OIG) offers important and practical guidance for pharmaceutical and medical device manufacturers on its approach to evaluating discount and rebate arrangements under the Federal Anti-Kickback Statute (AKS)….
By: Gardner Law
Previous Story

First Mover Advantage: How New Rule 16.1 Rewards the Prepared in Multidistrict Litigation

Next Story

Clark Hill 2026 Commercial Real Estate Market Update: CIRCIA Is Coming – What Commercial Real Estate and Facilities Owners Need to Know About Cyber Incident Reporting